ASLAN Pharmaceuticals Limited Stock Taipei Exchange
Equities
6497
KYG054241099
Biotechnology & Medical Research
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 307M 9.41M |
---|---|---|---|---|---|
Net income 2024 * | -2.14B -65.53M | Net income 2025 * | -1.82B -55.83M | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-0.11
x | P/E ratio 2025 * |
-0.17
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99% |
Managers | Title | Age | Since |
---|---|---|---|
Founder | 51 | 09-12-31 | |
Director of Finance/CFO | 45 | 10-10-31 | |
Chief Tech/Sci/R&D Officer | - | 22-03-14 |
Members of the board | Title | Age | Since |
---|---|---|---|
Robert Hoffman
BRD | Director/Board Member | 58 | 18-10-29 |
Chairman | 64 | 16-03-31 | |
Founder | 51 | 09-12-31 |
1st Jan change | Capi. | |
---|---|---|
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |